Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes any known death after randomisation (fetal, neonatal, child, child… compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes respiratory distress syndrome compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes intraventricular haemorrhage compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes necrotising enterocolitis compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal blood loss of 500 mL or greater · women in the third stage of labour
Oxytocin + ergometrine may leads to lower blood loss 500 mL or more after delivery compared with ergot alkaloids (low certainty).
1 finding from 1 review
Need for additional uterotonics · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal mortality ‐ not reported · women in the third stage of labour
1 finding from 1 review
Severe PPH (≥ 1000 mL) · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Third stage > 30 minutes · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diastolic blood pressure > 100 mm Hg between delivery of the baby and discharge from the labour ward · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether betamethasone 12‐hourly changes any known death after randomisation (fetal, neonatal, child, child… compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether betamethasone 12‐hourly changes respiratory distress syndrome compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review